作者: Hamid Kashkar , Anke Deggerich , Jens-Michael Seeger , Benjamin Yazdanpanah , Katja Wiegmann
DOI: 10.1182/BLOOD-2006-10-053959
关键词: Cancer research 、 Proteasome inhibitor 、 Downregulation and upregulation 、 NF-κB 、 XIAP 、 Cytotoxicity 、 Biology 、 Bortezomib 、 Cytotoxic T cell 、 Cell culture
摘要: The proteasome inhibitor bortezomib has been shown to possess promising antitumor activity and significant efficacy against a variety of malignancies. Different studies demonstrated that breaks the chemoresistance in different tumor cells basically by altering nuclear factor–κB (NF-κB) activity. NF-κB be constitutively active most primary Hodgkin-Reed-Sternberg (H-RS) lymph node sections Hodgkin lymphoma (HL) cell lines was suggested central molecular switch apoptosis resistance HL. Here we report bimodal effect HL cells. Whereas high-dose induced direct cytotoxicity correlated with decreased activity, low-dose sensitized cytotoxic drugs without action. Strikingly, marked XIAP down-regulation at posttranslational level independent status. Similarly, RNA interference (RNAi)–mediated generated susceptibility cytostatic agents. results identify as an NF-κB–independent target action controls chemoresistant phenotype